Asthma

Last updated: October 12, 2023
Sponsor: AstraZeneca
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

N/A

Clinical Study ID

TX319897
  • Ages 12-80
  • All Genders

Study Summary

A 24-week to 52-week length Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Triple-combination therapy in Adult and Adolescent Participants with Inadequately Controlled Asthma, to demonstrate benefits on improving lung function, health-related quality of life and rate of severe asthma exacerbations.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Participants Must be at Least 12- 80 Years of Age.
  • Participants Must be on a Stable Daily ICS/LABA Regimen for at Least 4 Weeks.
  • Participants Must have a documented history of physician-diagnosed asthma for at least 1 year.
  • Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months prior to visit 1 (including all forms of tobacco, e-cigarettes, or other vaping devices, and marijuana.

Study Design

Study Start date:
October 05, 2023
Estimated Completion Date:

Study Description

This study is a 60 week (420 days) with 15 in office visits and 1 follow-up phone call.

Connect with a study center

  • Elite Clinical Studies, LLC

    Phoenix, Arizona 85018
    United States

    Active - Recruiting

    0.79 miles

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.